Foresee Pharmaceuticals announces interim results for FP-025 phase 2a trial in allergic asthma
Exhibitor: FORESEE PHARMACEUTICALS CO., LTD.
Booth No.: R202
Taipei, Taiwan, Nov 4th, 2021 - Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the interim results for FP-025 phase 2a trial in allergic asthma. FP-025 is safe, well tolerated and a trend in improvement of the late asthmatic response.
This phase 2a clinical trial is a first-in-patient, proof-of-concept study; it's a randomized, placebo-controlled, double-blind, 2-way crossover study in a total of 36 enrolled subjects with stable, mild house-dust-mite-allergic asthma. The study consists of two identical study periods of 12 treatment days each, separated by a washout period of at least 3 weeks (and no more than 7 weeks). The subjects were treated with both FP-025 (400 mg BID) or matching placebo in a cross-over design.
The interim analysis is based on a total of 26 subjects enrolled in the clinical trial, including 21 evaluable subjects. Based on the interim analysis, FP-025 is safe and well tolerated; in addition, a trend in improvement of the late asthmatic response (LAR) to HDM was observed in patients while under FP-025 treatment versus placebo.
As such, the PIs (principal investigators) of this trial recommended that Foresee continue the clinical trial until a total of 36 subjects are enrolled, after which a final analysis will be conducted. Foresee plans to engage in licensing discussions upon successful completion of the study.
More Exhibitor's Press Release
- GoldenBiotech Oral COVID-19 Drug Antroquinonol Agreed by FDA to Extend Recruiting Severe Patients GOLDEN BIOTECHNOLOGY CORP. / 2021-12-14
- GoldenBiotech and Sanova Pharma Signs MOU for Cooperation of Antroquinonol in 23 European Countries GOLDEN BIOTECHNOLOGY CORP. / 2021-12-14
- Carbon-14 Metabolism Technology and Analysis Platform INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN / 2021-11-04
- Is your PCR instruments with great precision? STARMOONTECH CO., LTD. / 2021-10-31
- I can hold everything ! STARMOONTECH CO., LTD. / 2021-10-31
- CerbACT Asia Holds Ribbon Cutting to Celebrate New Immuno-oncology Centre of Excellence CERBACT ASIA / 2021-10-29
- National Tsing ua University Product &amp;amp;amp;amp;amp;amp;amp;amp;amp; Technology Presentation in 2021 Bio Asia NTHU LS BIO-APP INDUSTRY-ACADEMIA ALLIANCE / 2021-10-29
- INORA Brand Strategy to Drive Revenue Growth INORA PHARMACEUTICAL MACHINERY CO., LTD. / 2021-10-20
- 元健大和，犧牲三成營收的數位競爭思維 雲端給它機會搞破壞！助聽器小蝦米崛起戰記 DIGIBIONIC LIFESTYLE CO., LTD. / 2021-10-18
- 元健助聽器榮獲經濟部擴大投資 再啟數位雲端助聽器新局 DIGIBIONIC LIFESTYLE CO., LTD. / 2021-10-18
- Formosa Pharmaceuticals announce registration on Emerging Stock Board of the Taipei Stock Exchange FORMOSA PHARMACEUTICALS , INC / 2021-10-12
- GrowTrend : Breathing care at home service GROWTREND BIOMEDICAL CO., LTD. / 2021-09-27
- award of FSS for the Intellisense Drill MCGINLEY ORTHOPEDICS / 2021-09-24
- McGinley Orthopedics Changing the Standard of Care MCGINLEY ORTHOPEDICS / 2021-09-24
- Intelligent gas sensing chip (I+NOSE) with ultra-low power consumption TAIWAN INTELLIGENT POLLUTANTS SENSING (TIPS) / 2021-09-17
- The high accuracy cancer screening service that focus on the early stage JUN ZHI BIOMEDICAL CO., LTD / 2021-09-17
- Lab scale cultivation equipment (Polycel series) MICRO-GIANT BIOENGINEERING CO.,LTD. / 2021-09-17
- Liebherr appliances ensure safe storage of vaccine DOUBLE EAGLE ENTERPRISE CO., LTD. / 2021-09-16
- Congratulations to Ducolege ‘s Award of 2021 Taiwan Top 10 - Cosmetic Products! DUCOLEGE BIOTECHNOLOGY CO., LTD. / 2021-09-15
- Spreading love to EB Ducolege Biotechnology uses highly active collagen to care for wounds DUCOLEGE BIOTECHNOLOGY CO., LTD. / 2021-09-15